Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Receives NYS Approval for Cancer Test

NEW YORK (GenomeWeb) – The New York State Department of Health has approved Response Genetics to market and report results from its ResponseDX tests to residents of the state, the company said today. 

The New York approval follows a two-day inspection of Response Genetics' CLIA laboratory in September. 

The company offers ResponseDX Biomarker tests for various cancer types, including lung, breast, and colon cancer. The tests use different technologies such as sequencing, PCR, and fluorescence in situ hybridization. Response Genetics also offers the microarray-based ResponseDX: Tissue of Origin Test for identifying challenging tumors, such as metastatic, poorly differentiated, and undifferentiated cancer. 

Response Genetics acquired the test when it bought the assets of Pathwork Diagnostics in 2013. 

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.